Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 26 04:00PM ET
14.79
Dollar change
+0.03
Percentage change
0.20
%
Index- P/E- EPS (ttm)-0.74 Insider Own89.09% Shs Outstand350.91M Perf Week1.02%
Market Cap5.19B Forward P/E17.09 EPS next Y0.87 Insider Trans0.00% Shs Float38.30M Perf Month-14.06%
Income-260.00M PEG- EPS next Q0.07 Inst Own11.23% Short Float4.25% Perf Quarter2.92%
Sales4.15B P/S1.25 EPS this Y-13.28% Inst Trans20.84% Short Ratio3.47 Perf Half Y-9.15%
Book/sh19.52 P/B0.76 EPS next Y36.68% ROA-2.12% Short Interest1.63M Perf Year-12.74%
Cash/sh0.95 P/C15.54 EPS next 5Y16.00% ROE-3.75% 52W Range13.62 - 21.95 Perf YTD-13.31%
Dividend Est.- P/FCF- EPS past 5Y- ROI-2.27% 52W High-32.62% Beta0.46
Dividend TTM- Quick Ratio1.09 Sales past 5Y2.77% Gross Margin54.61% 52W Low8.59% ATR (14)0.51
Dividend Ex-Date- Current Ratio1.74 EPS Y/Y TTM- Oper. Margin4.92% RSI (14)41.48 Volatility2.23% 3.64%
Employees13300 Debt/Eq0.68 Sales Y/Y TTM10.03% Profit Margin-6.27% Recom2.00 Target Price18.98
Option/ShortYes / Yes LT Debt/Eq0.67 EPS Q/Q-5206.90% Payout- Rel Volume0.40 Prev Close14.76
Sales Surprise6.03% EPS Surprise41.84% Sales Q/Q17.77% EarningsMay 01 BMO Avg Volume469.96K Price14.79
SMA20-3.99% SMA50-6.85% SMA200-10.67% Trades Volume186,397 Change0.20%
Date Action Analyst Rating Change Price Target Change
Jan-04-24Downgrade Evercore ISI Outperform → In-line $19 → $17
Dec-12-23Initiated Stifel Hold $16
Oct-03-23Resumed Evercore ISI Outperform $20
May-30-23Resumed Morgan Stanley Equal-Weight $20
Mar-09-23Initiated Needham Hold
Dec-21-22Initiated Barclays Equal Weight $17
Sep-12-22Initiated H.C. Wainwright Buy $21
Jul-26-22Initiated RBC Capital Mkts Outperform $22
Jun-24-22Initiated Evercore ISI Outperform $21
Jun-06-22Initiated Citigroup Buy
Apr-25-24 08:30AM
Apr-24-24 10:01AM
Apr-18-24 07:00AM
Apr-15-24 12:00PM
Mar-27-24 07:00AM
12:00PM Loading…
Mar-25-24 12:00PM
Mar-20-24 12:20PM
Mar-19-24 08:50AM
Mar-08-24 10:10AM
Feb-28-24 08:00AM
Feb-23-24 03:05PM
Feb-22-24 11:30AM
Feb-21-24 10:35PM
07:04PM
09:30AM
07:36AM Loading…
07:36AM
07:31AM
07:00AM
06:58AM
Feb-15-24 09:15AM
Feb-14-24 12:10PM
10:00AM
Feb-05-24 12:00PM
Jan-17-24 06:54PM
Jan-09-24 12:41PM
Jan-08-24 06:59AM
Jan-03-24 09:00AM
Nov-28-23 01:25PM
Nov-15-23 06:59AM
Nov-03-23 11:01AM
03:19PM Loading…
Nov-01-23 03:19PM
09:21AM
06:58AM
Oct-26-23 06:59AM
Oct-16-23 12:00PM
Oct-04-23 06:59AM
Sep-29-23 10:15AM
10:00AM
Sep-26-23 06:59AM
Sep-20-23 06:59AM
Sep-19-23 08:32AM
Sep-18-23 11:56AM
Sep-14-23 05:25PM
Sep-12-23 06:59AM
Sep-11-23 08:00AM
07:07AM
Sep-06-23 05:58PM
06:59AM
Aug-29-23 07:00AM
Aug-24-23 07:00AM
Aug-02-23 05:25PM
06:59AM
Aug-01-23 08:00AM
Jul-11-23 07:00AM
Jul-06-23 07:00AM
Jul-03-23 10:12AM
Jun-30-23 06:48PM
08:30AM
08:28AM
08:00AM
Jun-14-23 09:43AM
Jun-12-23 07:00AM
Jun-08-23 07:00AM
Jun-06-23 07:00AM
Jun-05-23 07:00AM
Jun-01-23 07:00AM
May-18-23 01:56PM
08:50AM
May-08-23 06:53PM
May-03-23 06:59AM
May-01-23 07:00AM
Apr-26-23 07:00AM
Apr-25-23 07:00AM
Apr-24-23 07:00AM
Apr-20-23 07:00AM
Apr-18-23 11:02AM
07:00AM
Apr-17-23 07:00AM
Apr-13-23 07:00AM
Apr-12-23 07:00AM
Mar-31-23 10:15PM
Mar-29-23 04:39PM
Mar-22-23 07:00AM
Mar-08-23 07:02PM
Feb-23-23 10:47PM
05:28AM
Feb-22-23 06:59AM
Feb-15-23 07:02PM
07:30AM
06:58AM
Feb-07-23 07:00AM
Feb-01-23 07:00AM
Jan-23-23 07:00AM
Jan-17-23 05:09PM
Jan-13-23 02:19PM
Jan-09-23 08:00AM
07:00AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Jan-03-23 07:00AM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Last Close
Apr 26 04:00PM ET
8.71
Dollar change
+0.09
Percentage change
1.04
%
BHC Bausch Health Companies Inc daily Stock Chart
Index- P/E- EPS (ttm)-1.62 Insider Own2.41% Shs Outstand365.24M Perf Week0.23%
Market Cap3.18B Forward P/E2.13 EPS next Y4.10 Insider Trans-0.07% Shs Float356.59M Perf Month-16.97%
Income-592.00M PEG- EPS next Q0.69 Inst Own79.22% Short Float5.81% Perf Quarter6.48%
Sales8.76B P/S0.36 EPS this Y12.75% Inst Trans19.06% Short Ratio7.34 Perf Half Y26.05%
Book/sh-2.80 P/B- EPS next Y4.68% ROA-2.23% Short Interest20.71M Perf Year23.37%
Cash/sh2.63 P/C3.31 EPS next 5Y2.60% ROE- 52W Range5.57 - 11.46 Perf YTD8.60%
Dividend Est.- P/FCF4.11 EPS past 5Y32.76% ROI-2.81% 52W High-24.00% Beta0.90
Dividend TTM- Quick Ratio0.94 Sales past 5Y1.03% Gross Margin58.48% 52W Low56.37% ATR (14)0.39
Dividend Ex-DateAug 30, 2010 Current Ratio1.30 EPS Y/Y TTM-160.23% Oper. Margin18.34% RSI (14)42.25 Volatility2.77% 5.25%
Employees20270 Debt/Eq- Sales Y/Y TTM7.79% Profit Margin-6.76% Recom2.86 Target Price10.17
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q90.57% Payout- Rel Volume0.74 Prev Close8.62
Sales Surprise4.99% EPS Surprise-4.77% Sales Q/Q9.80% EarningsMay 02 BMO Avg Volume2.82M Price8.71
SMA20-5.73% SMA50-5.89% SMA2004.90% Trades Volume2,076,307 Change1.04%
Date Action Analyst Rating Change Price Target Change
Sep-20-23Upgrade Jefferies Hold → Buy $9 → $16
Jun-16-23Downgrade TD Cowen Outperform → Market Perform
Jul-29-22Downgrade Truist Buy → Hold
Jul-29-22Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $5
Jul-28-22Downgrade JP Morgan Overweight → Neutral
Jun-13-22Resumed JP Morgan Overweight $12
Mar-24-21Downgrade BofA Securities Neutral → Underperform $27
Feb-17-21Upgrade RBC Capital Mkts Sector Perform → Outperform $26 → $42
Jan-22-21Downgrade Piper Sandler Overweight → Neutral $25 → $30
Sep-17-20Upgrade BofA Securities Underperform → Neutral $19
Apr-25-24 02:27PM
09:02AM
Apr-23-24 12:04PM
Apr-22-24 12:41PM
Apr-20-24 09:16AM
04:22PM Loading…
Apr-11-24 04:22PM
01:03PM
12:40PM
12:10PM
11:17AM
11:03AM
08:00AM
Apr-08-24 05:33PM
01:27PM
Apr-05-24 06:15PM
12:05PM Loading…
Apr-03-24 12:05PM
09:50AM
08:00AM
Apr-02-24 08:00AM
Mar-28-24 02:19PM
05:23AM
Mar-15-24 09:50AM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
Mar-01-24 08:00AM
Feb-27-24 03:27AM
Feb-23-24 12:25PM
11:53AM
Feb-22-24 11:30AM
10:03AM
09:30AM Loading…
09:30AM
08:25AM
07:33AM
07:33AM
07:00AM
Feb-21-24 12:10PM
07:26AM
Feb-19-24 09:15AM
Feb-15-24 10:00AM
Feb-12-24 08:00AM
Feb-08-24 10:59AM
Feb-07-24 12:00PM
Feb-01-24 04:10PM
08:00AM
Jan-31-24 04:00PM
Jan-30-24 05:54PM
08:00AM
Jan-18-24 04:50PM
08:00AM
Jan-08-24 11:15AM
Dec-22-23 10:23AM
Dec-21-23 07:00AM
Dec-18-23 09:40AM
08:00AM
Dec-13-23 07:43AM
Dec-11-23 09:55AM
Dec-05-23 08:00AM
Nov-30-23 09:40AM
Nov-24-23 09:55AM
Nov-13-23 09:55AM
Nov-10-23 12:42PM
08:00AM
Nov-08-23 08:00AM
Nov-03-23 02:03PM
12:47PM
Nov-02-23 04:13PM
11:00AM
09:41AM
08:34AM
07:00AM
Nov-01-23 12:22PM
10:43AM
10:40AM
09:30AM
07:07AM
Oct-31-23 02:58AM
Oct-30-23 04:35PM
Oct-26-23 10:02AM
10:02AM
08:00AM
Oct-25-23 10:02AM
Oct-20-23 05:20PM
Oct-17-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-04-23 08:00AM
Sep-29-23 10:15AM
Sep-26-23 08:54AM
Sep-21-23 11:16AM
08:00AM
Sep-20-23 11:25AM
10:50AM
Sep-19-23 04:32PM
02:37PM
01:46PM
11:47AM
Sep-18-23 05:45PM
Sep-15-23 08:25AM
Sep-12-23 08:00AM
Sep-11-23 04:04PM
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carson SeanaEVP, General CounselMar 04 '24Sale9.806,31361,867499,905Mar 04 04:16 PM
Carson SeanaEVP, General CounselDec 05 '23Sale7.382201,624382,925Dec 05 04:35 PM
Carson SeanaEVP, General CounselNov 06 '23Sale7.6143327384,836Nov 06 05:06 PM
Carson SeanaEVP, General CounselSep 06 '23Sale8.286,68555,352385,213Sep 06 04:33 PM